inotuzumab
pfizer,ucb pharmaceuticals
['leusm', 'inotuzumab']
congress | #ash22
leland metheny, , presents phase i data of post-transplant low-dose maintenance inotuzumab ozogamicin in relapsed all (n = 18). 1-year post-hsct os = 94% &amp; pfs = 89%. 1-year trm = 56%. most common g3/4 ae was thrombocytopenia. mtd = 0.6mg/m2.
#leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm